<DOC>
	<DOCNO>NCT00920192</DOCNO>
	<brief_summary>The purpose study assess safety tolerability foretinib ( also know GSK1363089 ) use treatment patient advance hepatocellular carcinoma ( liver cancer ) .</brief_summary>
	<brief_title>Safety Study Foretinib ( GSK1363089 ) Adults With Liver Cancer</brief_title>
	<detailed_description>The purpose study identify maximum tolerate dose ( MTD ) foretinib ( also know GSK1363089 ) use treatment patient advance hepatocellular carcinoma ( liver cancer ) , assess safety tolerability dose patient population . The MTD identify Phase I , standard dose-escalation foretinib . Then Phase II ass safety tolerability foretinib dose MTD .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Signed informed consent 18 year old Eastern Cooperative Oncology Group performance status 0 1 Has histologically cytologically confirm advanced ( unresectable and/or metastatic ) hepatocellular carcinoma ( HCC ) . Has adequate organ system function Has least 1 target tumor lesion . Has ability swallow retain oral medication Has life expectancy least 12 week If male : Agrees use doublebarrier contraception , OR Agrees complete abstinence sexual intercourse 14 day exposure investigational product , clinical trial , least 21 day last dose investigational product If female : Is nonchildbearing potential OR Is childbearing potential negative serum pregnancy test within 14 day first dose study drug , agree use adequate contraception . Has previously use investigational agent license drug inhibits multiple receptor tyrosine kinase Is currently receive cancer therapy Is currently receive treatment investigational agent , include investigational anticancer agent Has ChildPugh score &gt; 6 Has AEs due investigational drug medication administer 21 day enrollment recover Grade 1 less exception alopecia great Grade 1 Has receive local therapy within follow timeframes subject fully recover prior therapy : Radiotherapy : le 28 day since completion prior radiotherapy Chemoembolization , hepatic arterial embolization , percutaneous ethanol injection , cryoablation : le 42 day since completion prior therapy Radiofrequency ablation : le 60 day since completion prior therapy Surgery : ( 1 ) prior surgical procedure affect absorption , ( 2 ) less 28 day since last prior major surgery Has history clinical evidence central nervous system metastasis leptomeningeal carcinomatosis Has history malabsorption syndrome , medical condition significantly affect gastrointestinal function , resection stomach small bowel Has active peptic ulcer disease , inflammatory bowel disease , gastrointestinal condition increase risk perforation , history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within past 28 day Has know immediate delay hypersensitivity idiosyncratic reaction drug chemically relate foretinib . Has QTcB ( Bazettcorrected QT interval ) QTcF ( Fredericacorrected QT interval ) great equal 470 msec ( 500 msec subject bundle branch block ) . Has history one follow cardiac condition procedure within past 6 month : Cardiac angioplasty stenting Myocardial infarction Unstable angina Has history cerebrovascular accident within past 6 month Has Class III IV heart failure define New York Heart Association functional classification system Has poorly control hypertension ( systolic blood pressure 140 mm Hg great diastolic blood pressure 90 mm Hg great ) Has history untreated deep venous thrombosis within past 6 month ( e.g. , calf vein thrombosis ) Has history main portal vein thrombosis Has presence nonhealing wound , fracture , ulcer , presence symptomatic peripheral vascular disease Has previous concurrent cancer distinct primary site histology HCC , except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( tumor stage Ta , Tis , T1 ) . Any cancer curatively treat 3 year study entry permit . Has history bleeding varix within past 30 day Has clinically significant gastrointestinal bleeding within past 30 day Is pregnant lactate female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>c-MET</keyword>
	<keyword>Advanced hepatocellular carcinoma</keyword>
	<keyword>VEGFR2</keyword>
</DOC>